Background: Testing to determine HER2 status has come into focus since the approval of
trastuzumab (Herceptin) for the treatment of HER2-positive breast cancer. We compared the …

HER2 status is of great clinical value in breast tumors for the identification of those patients
who are eligible for trastuzumab therapy. There is a debate about the advantages and …

Background Women with HER2-overexpressing breast cancer have an unfavorable
prognosis. Trastuzumab improves survival when combined with chemotherapy in the first …

BACKGROUND: Molecular techniques play an increasingly important role in breast cancer
detection and help in the prediction of prognosis and treatment response. HER-2/neu …

The need for accurate detection of HER2 status is becoming more apparent, as therapeutic
decisions are influenced by this information in both the adjuvant and advanced-stage …

Abstract The American Society of Clinical Oncologists and College of American Pathologists
have recently released new guidelines for laboratory testing of HER2 status in breast …

Clinical laboratory testing for human epidermal growth factor receptor 2 (HER2) status in
newly diagnosed breast cancer is critically important for therapeutic decision making. Unlike …

The NCCN HER2 Testing in Breast Cancer Task Force was convened to critically evaluate
the ability of the level of HER2 expression or gene amplification in breast cancer tumors to …

Several recent publications have re-opened the question of whether HER2 status should be
determined for all patients with newly diagnosed breast cancer. The barrier in the past to the …

Overexpression and/or gene amplification of the HER2 oncogene predicts worse prognosis
and altered sensitivity to chemotherapy. Trastuzumab is capable of improving prognosis of …